The print · 8-K and call2026-11-05 · Pre-market
Revenue$85M
est. —
EPS—
est. —
Guidance · FY revenue$344.0M–$346.0M
vs consensus +2.6% · Consensus $336.2M
Vericel Corporation · Biotechnology
VCEL Vericel Corporation · Earnings
Reports 2026-11-05 Pre-market · ThuReaction day 11-05reported · reaction in progress
Get VCEL's results by email the night it reports
EPS and revenue vs. estimates, plus the first-day move. Free — unsubscribe in one click.
Report card
Done· 8-K + call· 11-05 Pre-marketBreakdown
Key figures, the focus-point check, management quotes, the sector read and the grade are in the full view. Start 30-day free trial →
Reaction
Now· open / day / 5-day· 11-05 → day 5Reactionreaction not yet settled
After-hours move—pre-market print, no after-hours read
Open / day close— / +14.1%Move so far · as of 16:10
5 days later—day 5 pending
Going in
Done· T-7 → T-1 freezeBefore the print · expectationsfrozen at T-1
No past prints on file yet.
Pricing going in · as of the 11-04 close
+11.6%Move over the last 20 sessionsLast 5 sessions +10.7%
−0.7 ptsvs sector (XLV)XLV over the same window +12.4%
—Forward P/EConsensus: not available
What the record doesn't tell you
Which way does VCEL go on 11‑05?
- Model lean for 11-05, and the evidence behind it
- Move band, P10 – P90
- Last 8 prints, quarter by quarter
- Peers that already reported, and how they traded
Lean, stance and evidence on this page are model outputs, not investment advice. Trade at your own risk. Disclaimer →
Vericel earnings review: what the record says
Vericel (VCEL) reported earnings on Nov 5, 2026, before the open. The company posted revenue of $85M.
NextPick tracks VCEL in its Cell / Gene Therapy basket alongside CRSP, BEAM, NTLA, PRME, EDIT and FATE, whose prints read through to this one.
Figures come from NextPick's earnings-reaction ledger and the options market. Not investment advice.